Skip to content
Elisabetta Bonzano MD, PhD路 @to_be_elizabeth 路 X路路 2 days agoScore70

DESTINY-BREAST05

Body

馃搶 Rapid Oral Breast Cancer, Early stage
鉁≒atient-reported outcomes from DESTINY-Breast05: HRQoL with T-DXd versus T-DM1 in patients with high-risk HER2-positive eBC
#ESMO26 馃嚜馃嚫 @OncoAlert #OncoAlertAF

235 views 路 6 likes 路 5 reposts 路 0 replies

Conference abstracts
539ROmatched by Rapid oral: Breast cancer, early stage

Patient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)

https://esmocongress.esmo.org

Source: Elisabetta Bonzano MD, PhD 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org